Sunday, November 24, 2013
An article by Regents’ Professor Gary Marchant, Faculty Director of the College of Law’s Center for Law, Science & Innovation, was featured November 26th on the Slate website.
The article, The FDA Could Set Personal Genetics Rights Back Decades: Its Letter to 23andMe is Foolish and Paternalistic,” discusses the U.S. Food and Drug Administration’s recent directive to the company 23andMe to stop marketing its genetic tests directly to consumers without pre-market approval.
Such approval would take several years and cost millions of dollars for each of the more than 250 diseases and conditions for which 23andMe provides tests, making it impractical in terms of money and time. New, more precise tests would be available before the process could be completed, Marchant wrote.
Marchant also argued that private physicians are offering genetic tests not approved by the FDA, but charging far more than the $99 23andMe is charging and that the FDA’s heavy-handed approach will cut off consumer access just at a time when genetic information is becoming relevant and useful.
Read the entire article here.
Marchant’s research interests include the use of genetic information in environmental regulation, risk and the precautionary principle, legal aspects of personalized medicine, and regulation of emerging technologies such as nanotechnology, neuroscience and biotechnology. He teaches courses in Environmental Law, Law, Science & Technology, Genetics and the Law, Biotechnology: Science, Law and Policy, and Nanotechnology Law & Policy. He was named a Regents' Professor in 2011, is the Lincoln Professor of Emerging Technologies, Law and Ethics and also is a professor in ASU’s School of Life Sciences.
Categories: News, Faculty NotesNumber of views: 3484